Deerfield Management Company, L.P. (Series C) Protara Therapeutics, Inc. Call Options Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TARA
# of Institutions
39Shares Held
10.7MCall Options Held
9KPut Options Held
1.8K-
Ra Capital Management, L.P. Boston, MA1.9MShares$11.9 Million0.05% of portfolio
-
Opaleye Management Inc. Boston, MA1.68MShares$10.5 Million0.56% of portfolio
-
Stem Point Capital LP New York, NY943KShares$5.89 Million0.52% of portfolio
-
Woodline Partners LP San Francisco, CA852KShares$5.32 Million0.01% of portfolio
-
Boxer Capital, LLC San Diego, CA812KShares$5.07 Million0.08% of portfolio
About Protara Therapeutics, Inc.
- Ticker TARA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,267,400
- Market Cap $70.4M
- Description
- Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chlorid...